APOB

Across TCGA pan-cancer cohorts, APOB Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated APOB data layer compared with 29 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher APOB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated APOB expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

ACC, ESCA, and UCS are the cancer types where APOB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.624	<.001	34	view →
ESCA	OS	Median	II,III,IV	0.328	0.707	<.001	17	view →
UCS	OS	Median	III,IV	0.196	0.602	.011	12	view →
SCLC	OS	Median	III,IV	0.312	0.682	.001	12	view →
LUAD	OS	Median	III,IV	0.287	0.556	.010	8	view →
READ	OS	Median	All	0.281	0.830	.006	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SARC	DFS	Median	All	0.176	0.605	<.001	3	view →
LIHC	DFS	Median	III,IV	0.166	0.439	.043	3	view →
STAD	DFS	Median	All	0.655	0.374	.040	2	view →
BRCA	DFS	Median	All	0.824	0.904	.021	2	view →
UCEC	DFS	Median	All	0.826	0.598	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

APOB–ACC (DFS)

Open the ACC breakdown →